Cisplatin Restores TRAIL Apoptotic Pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP

REFERENCES

• Stupp R, Mason WP, van den Bent MJ, WellerM, FisherB, TaphoornMJ, BelangerK, BrandesAA, MarosiC, BogdahnU, CurschmannJ, JanzerRC, LudwinSK, GorliaT, AllgeierA, LacombeD, CairncrossJG, EisenhauerE, MirimanoffRO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002;39:193–206.
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M, BonnVE, HawkinsC, SquireJ, DirksPB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–8.
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, SquireJA, BayaniJ, HideT, HenkelmanRM, CusimanoMD, DirksPB. Identification of human brain tumour initiating cells. Nature 2004;432:396–401.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, HaoY, ShiQ, HjelmelandAB, DewhirstMW, BignerDD, RichJN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756–60.
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z, TuniciP, NgH, AbdulkadirIR, LuL, IrvinD, BlackKL, YuJS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
   PubMed Web of Science ®Google Scholar
• Murat A, Migliavacca E, Gorlia T, LambivWL, ShayT, HamouMF, de TriboletN, RegliL, WickW, KouwenhovenMC, HainfellnerJA, HeppnerFL, DietrichPY, ZimmerY, CairncrossJG, JanzerRC, DomanyE, DelorenziM, StuppR, HegiME. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015–24.
   PubMedGoogle Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755–68.
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U, CipellettiB, GrittiA, De VitisS, FioccoR, ForoniC, DimecoF, VescoviA. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011–21.
   PubMed Web of Science ®Google Scholar
• Yuan X, Curtin J, Xiong Y, LiuG, Waschsmann-HogiuS, FarkasDL, BlackKL, YuJS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23:9392–400.
   PubMed Web of Science ®Google Scholar
• Lee J, Kotliarova S, Kotliarov Y, LiA, SuQ, DoninNM, PastorinoS, PurowBW, ChristopherN, ZhangW, ParkJK, FineHA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9: 391–403.
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S, HaoY, LiZ, HjelmelandAB, ShiQ, McLendonRE, BignerDD, RichJN. Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor. Cancer Res 2006;66:7843–8.
   PubMed Web of Science ®Google Scholar
• Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009;4:440–52.
   PubMed Web of Science ®Google Scholar
• Lee J, Son MJ, Woolard K, DoninNM, LiA, ChengCH, KotliarovaS, KotliarovY, WallingJ, AhnS, KimM, TotonchyM, CusackT, EneC, MaH, SuQ, ZenklusenJC, ZhangW, MaricD, FineHA. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69–80.
   PubMed Web of Science ®Google Scholar
• Piccirillo SG, Reynolds BA, Zanetti N, LamorteG, BindaE, BroggiG, BremH, OliviA, DimecoF, VescoviAL. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761–765.
   PubMed Web of Science ®Google Scholar
• Bar EE, Chaudhry A, Lin A, FanX, SchreckK, MatsuiW, PiccirilloS, VescoviAL, DiMecoF, OliviA, EberhartCG. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25:2524–33.
   PubMed Web of Science ®Google Scholar
• Diamandis P, Wildenhain J, Clarke ID, SacherAG, GrahamJ, BellowsDS, LingEK, WardRJ, JamiesonLG, TyersM, DirksPB. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol 2007;3:268–73.
   PubMed Web of Science ®Google Scholar
• Li Z, Bao S, Wu Q, WangH, EylerC, SathornsumeteeS, ShiQ, CaoY, LathiaJ, McLendonRE, HjelmelandAB, RichJN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501–13.
   PubMed Web of Science ®Google Scholar
• Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124–31.
   PubMed Web of Science ®Google Scholar
• Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806–23.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782–98.
   PubMed Web of Science ®Google Scholar
• Hao C, Beguinot F, Condorelli G, TrenciaA, Van MeirEG, YongVW, ParneyIF, RoaWH, PetrukKC. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001;61:1162–70.
   PubMed Web of Science ®Google Scholar
• Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 2001;20:5789–98.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001;7:1362–9.
   PubMed Web of Science ®Google Scholar
• Bellail AC, Mulligan P, Hao C. Targeting of TRAIL apoptotic pathways for glioblastoma therapies. CNS CANCER, Cancer Drug Discovery and Development 2009;977–1009.
   Google Scholar
• Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002;277:25020–5.
   PubMed Web of Science ®Google Scholar
• Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C. TRAIL triggers apoptosis in malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003;13:539–53.
   PubMed Web of Science ®Google Scholar
• Bellail AC, Tse MC, Song JH, PhuphanichS, OlsonJJ, SunSY, HaoC. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med 14:1303–17.
   PubMed Web of Science ®Google Scholar
• Irmler M, Thome M, Hahne M, SchneiderP, HofmannK, SteinerV, BodmerJL, SchroterM, BurnsK, MattmannC, RimoldiD, FrenchLE, TschoppJ. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190–5.
   PubMed Web of Science ®Google Scholar
• Scaffidi C, Medema JP, Krammer PH, Peter ME. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem 1997;272:26953–8.
   PubMed Web of Science ®Google Scholar
• Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25:8809–23.
   PubMed Web of Science ®Google Scholar
• Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009;4:34–41.
   PubMedGoogle Scholar
• Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645–51.
   PubMed Web of Science ®Google Scholar
• Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004;96:1769–80.
   PubMed Web of Science ®Google Scholar
• Song JH, Song DK, Herlyn M, Petruk KC, Hao C. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res 2003;9:4255–66.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang J, Bellail A, JiangW, HughJ, KnetemanNM, HaoC. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007;19:2237–46.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, LeungS, LawrenceDA, MarstersSA, BlackieC, ChangL, McMurtreyAE, HebertA, DeForgeL, KoumenisIL, LewisD, HarrisL, BussiereJ, KoeppenH, ShahrokhZ, SchwallRH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–62.
   PubMed Web of Science ®Google Scholar
• Roth W, Isenmann S, Naumann U, KuglerS, BahrM, DichgansJ, AshkenaziA, WellerM. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999;265:479–83.
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Liu W, Zhao L, WangZ, LiuD, OhtsukaT, ZhangH, MountzJD, KoopmanWJ, KimberlyRP, ZhouT. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954–60.
   PubMed Web of Science ®Google Scholar
• Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707–10.
   PubMed Web of Science ®Google Scholar
• Laks DR, Masterman-Smith M, Visnyei K, AngenieuxB, OrozcoNM, ForanI, YongWH, VintersHV, LiauLM, LazareffJA, MischelPS, CloughesyTF, HorvathS, KornblumHI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009;27:980–7.
   PubMed Web of Science ®Google Scholar
• Hao C, Song JH, Vilimanovich U, Kneteman NM. Modulation of TRAIL signaling complex. Vitam Horm 2004;67:81–99.
   PubMed Web of Science ®Google Scholar
• Panner A, Murray JC, Berger MS, Pieper RO. Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res 2007;67:9482–9.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265–79.
   PubMed Web of Science ®Google Scholar
• Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430–46.
   PubMed Web of Science ®Google Scholar
• Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847–53.
   PubMed Web of Science ®Google Scholar
• Rohn TA, Wagenknecht B, Roth W, NaumannU, GulbinsE, KrammerPH, WalczakH, WellerM. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001;20:4128–37.
   PubMed Web of Science ®Google Scholar
• Saito R, Bringas JR, Panner A, TamasM, PieperRO, BergerMS, BankiewiczKS. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004;64:6858–62.
   PubMed Web of Science ®Google Scholar
• Wu GS, Burns TF, McDonald ER 3rd, JiangW, MengR, KrantzID, KaoG, GanDD, ZhouJY, MuschelR, HamiltonSR, SpinnerNB, MarkowitzS, WuG, el-DeiryWS. Killer/DR% is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141–3.
   PubMed Web of Science ®Google Scholar